Background and Aims

Insulin pump (CSII), continuous glucose monitoring (CGM) and sensor augmented pump (SAP) technology has evolved continuously over the last years. Aim of this study was to assess changes in use of these technologies over time and to identify potential issues regarding technology usage.

Methods

A large patient registry (Diabetes Prospective Follow-up Database, DPV) from Germany, Austria, Switzerland, and Luxembourg was used. The use of CSII, CGM, AID (automated insulin delivery) and SAP between 01/2018 and 06/2021 with T1D was analyzed depending on age, sex and region of care (see Table).

Results

43,835 patients with T1D treated in 416 diabetes centres between 2018 and 2021 met the inclusion criteria.

In group C, 56% of female patients used CSII and 36% SAP, whereas 47% of male patients used CSII and 29% SAP (both p<0.001).In group D, 53% female patients used CSII, 31% SAP and 69% CGM. Whereas 41% of the male patients used CSII, 23% SAP and 65% CGM (all p<0.001).There was a significant difference in the use of CSII, CGM and AID between the old and new federal states of Germany (CSII 55% versus 52%, CGM 76% versus 71%, AID 12% versus 8%; (all p<0.001)).

Conclusions

There has been an increase in the overall use of SAP and AID with the highest use in the younger age groups. A significant difference in the use of SAP between female and male patients could be demonstrated during puberty and in young adults. The new technologies are used more often in the old federal states of Germany.